For millions of women taking Premarin to ease their symptoms of menopause, including hot flashes, night sweats and vaginal dryness, a newly released study is another blow to finding relief for their discomfort.
According to a new Women’s Health Initiative study published in the Journal of the National Cancer Institute, women who take conjugated equine estrogen are at double the risk of developing benign proliferative breast disease. Tom Rohan, MBBS, Ph.D. of Albert Einstein College of Medicine and his colleagues report benign proliferative breast disease is thought to be an early stage of in the development of breast cancer and may increase the risk of later carcinoma.
Researchers looked at than 10,000 women from a previous hormone replacement trial who were given the HRT drug Premarin manufactured by Wyeth. 155 cases of non-cancerous proliferative breast disease were documented in women participating in Hormone Replacement Therapy (HRT) compared to 77 in women taking placebos.
This latest news, in addition to previous reports of serious side effects including increased risk of breast, uterine and ovarian cancer, heart attack, stoke, blot clots, dementia, and gall bladder disease, indicates that it’s time for Wyeth to do the right thing and stop putting profit before safety and issue a recall on their golden goose, Premarin. As successful as Premarin may have been for millions of women, studies are proving the risks are beginning to outweight the benefits and drug manufacturers should begin putting serious research dollars into HRT alternatives.